TG Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
TG Therapeutics, Inc. (TG) filed this Current Report on Form 8-K on March 10, 2017. The filing serves to announce the issuance of a press release detailing the Company's results of operations for the fourth quarter and the full year ended December 31, 2016.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the body of this 8-K.
Material Changes
No material changes or comparative financial data are disclosed within the text of this filing. The document solely notifies investors of the availability of the Q4 and full-year 2016 results.
Guidance, Outlook, and Management Commentary
Management announced an investor conference call scheduled for Friday, March 10, 2017, at 8:30 am ET. During this call, the Company intended to provide a brief overview of the fourth quarter and year-end financial results and offer a business outlook for the remainder of 2017.
Investor Verification Checklist
- Review the press release (Exhibit 99.1) for specific Q4 and full-year 2016 financial figures.
- Listen to the March 10, 2017 investor conference call for management's business outlook for 2017.
- Verify the Company's cash position and burn rate, as these are critical for a clinical-stage biopharmaceutical company not reporting revenue in this summary.